Comparison of adaptive and innate immune responses induced by licensed vaccines for human papillomavirus

The imperfect control of self-reactive germinal center B cells

(2014) Robert Brink   CURRENT OPINION IN IMMUNOLOGY

Toll-Like Receptor 7/8 (TLR7/8) and TLR9 Agonists Cooperate To Enhance HIV-1 Envelope Antibody Responses in Rhesus Macaques

(2014) M. A. Moody et al.   JOURNAL OF VIROLOGY

Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: Results from two randomized trials

(2014) Pierre Van Damme et al.   VACCINE

Durable Antibody Responses Following One Dose of the Bivalent Human Papillomavirus L1 Virus-Like Particle Vaccine in the Costa Rica Vaccine Trial

(2013) M. Safaeian et al.   Cancer Prevention Research

Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses

(2013) Mahboobeh Safaeian et al.   Human Vaccines & Immunotherapeutics

Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis

(2012) Talía Malagón et al.   LANCET INFECTIOUS DISEASES

Global burden of cancers attributable to infections in 2008: a review and synthetic analysis

(2012) Catherine de Martel et al.   LANCET ONCOLOGY

A Review of Clinical Trials of Human Papillomavirus Prophylactic Vaccines

(2012) John T. Schiller et al.   VACCINE

Human Papillomavirus Vaccines – Immune Responses

(2012) Margaret Stanley et al.   VACCINE

Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18–45 years

(2011) Mark H. Einstein et al.   Human vaccines & immunotherapeutics

Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine

(2011) Mark H. Einstein et al.   Human vaccines & immunotherapeutics

Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

(2011) Cosette M Wheeler et al.   LANCET ONCOLOGY

Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity

(2011) Tracy L Flach et al.   NATURE MEDICINE

HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection

(2011) Troy J. Kemp et al.   VACCINE

Multiplexed Serologic Assay for Nine Anogenital Human Papillomavirus Types

(2010) D. Opalka et al.   Clinical and Vaccine Immunology

Potential mechanisms for HPV vaccine-induced long-term protection

(2010) Margaret Stanley   GYNECOLOGIC ONCOLOGY

Comparison of the immunogenicity and safety ofCervarix™ andGardasil®human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years

(2010) Mark H. Einstein et al.   Human vaccines & immunotherapeutics

Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication

(2010) Ni Li et al.   INTERNATIONAL JOURNAL OF CANCER

Epidemiological Study of Anti-HPV16/18 Seropositivity and Subsequent Risk of HPV16 and -18 Infections

(2010) M. Safaeian et al.   JNCI-Journal of the National Cancer Institute

Impact of Human Papillomavirus (HPV)-6/11/16/18 Vaccine on All HPV-Associated Genital Diseases in Young Women

(2010) Nubia Muñoz et al.   JNCI-Journal of the National Cancer Institute

Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study

(2010) Silvia de Sanjose et al.   LANCET ONCOLOGY

T-helper 1 and T-helper 2 adjuvants induce distinct differences in the magnitude, quality and kinetics of the early inflammatory response at the site of injection

(2009) Karen Smith Korsholm et al.   IMMUNOLOGY

AS04, an Aluminum Salt- and TLR4 Agonist-Based Adjuvant System, Induces a Transient Localized Innate Immune Response Leading to Enhanced Adaptive Immunity

(2009) A. M. Didierlaurent et al.   JOURNAL OF IMMUNOLOGY

Immunogenicity Testing in Human Papillomavirus Virus‐Like‐Particle Vaccine Trials

(2009) John T. Schiller et al.   JOURNAL OF INFECTIOUS DISEASES

The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus‐Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV‐Naive Women Aged 16–26 Years

(2009) Darron R. Brown et al.   JOURNAL OF INFECTIOUS DISEASES

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

(2009) J Paavonen et al.   LANCET

Putting endotoxin to work for us: Monophosphoryl lipid A as a safe and effective vaccine adjuvant

(2008) C. R. Casella et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results

(2008) John T. Schiller et al.   VACCINE